Sound Therapy Could Help Cancer Patients

Interesting article by Mary Ann Childers.  Doctor Stands Behind The Science Of Sound.

Oncologist Mitchell Gaynor wrote a book on sound therapy. He says the body normally vibrates at certain frequencies, and when people are sick, they are out of tune. Vibrations from music or instruments work to reharmonize.

“The body is composed of 70percent water. It’s an excellent conductive medium for sound and vibration,” Gaynor said.

Full article at:


Welcome to the IMA’s Online Distant Healing Clinic

Great site to submit your healing requests

The Online Distant Healing Clinic is a public service for people who wish to give or receive free distant healing or healing prayer, or who wish to request that others in need receive distant healing or healing prayer.

Biotech firm criticised over Avastin ‘wonder drug’

Biotech firm Genentech criticised over Avastin ‘wonder drug’An American drug company is facing criticism from ophthalmologists for allegedly denying the legitimate use of a cheap and effective treatment for macular degeneration, in favour of a more expensive drug.

The Guardian (June 17) reported that some ophthalmologists were injecting tiny quantities of the colon cancer drug Avastin into patients’ eyes as a treatment for wet age-related macular degeneration (AMD). The results have been described as ‘remarkable’ and the cost is very little since one phial is enough to treat dozens of eyes.

AvastinA decade ago Genentech, the US company that makes Avastin, developed Lucentis, a ‘fragment’ of Avastin designed specifically for use in eyes. The NHS’s National Institute for Health and Clinical Excellence (Nice) is expected to decide whether Lucentis and another AMD drug, Macugen, should be available on the NHS in 2008.

The accusation is that Lucentis will be vastly more expensive than Avastin and that Genentech is not willing to trial and license Avastin for AMD treatment. Nice cannot consider Avastin for AMD use in the NHS if there is no licence for its use.

One of the main proponents of the use of Avastin for AMD is Philip Rosenfeld, associate professor of ophthalmology at the University of Miami.

This unlicensed or ‘off-label’ use of Avastin has grown in popularity with ophthalmologists worldwide. But while around 7,000 eyes have been treated with significant success, regulators require randomised controlled trials before they grant licences.

Only the drug companies involved can afford to carry out such trials.

In the Guardian article, Rosenfeld described Avastin as a ‘wonder drug’ but accused drug companies of being greedy. He proposed that governments fund clinical trials that are in the public interest.

A spokeswoman for Genentech told Optician that it had taken 10 years to get to the current position where Lucentis is up for approval by regulators.

The biotechnology company also expressed concerns that safety data on the use of Avastin for AMD are not being collected in a ‘standard or organised’ fashion.

A spokeswoman for Roche, which supplies Avastin in the UK, said it could not comment on off-label use of its products.

Bill Harvey, clinical editor of Optician commented: ‘In the current climate you can fully understand a drug company’s reluctance to allow the promotion of any unlicensed use of a drug.

But until fully controlled clinical trials of Avastin for AMD use are set up in Europe, one cannot dismiss that financial considerations are behind their reasoning.’

Painful questions of blame: Parents, doctors and the disputed link between vaccines and autism

Exerpt from article at:

By Meg McSherry Breslin
a Tribune staff reporter
Published June 25, 2006

After Blakey found a Chicago-area doctor willing to work with her son on a controversial treatment called chelation therapy–which removes mercury and other toxic metals from the body–she saw dramatic change in her son’s behavior. She said a wheat- and dairy-free diet has also produced positive changes, yet many doctors she initially consulted were skeptical.

What is quantum entanglement?

Entanglement is a strange feature of quantum physics, the science of the very small. It’s possible to link together two quantum particles – photons of light or atoms, for example – in a special way that makes them effectively two parts of the same entity. You can then separate them as far as you like, and a change in one is instantly reflected in the other. This odd, faster than light link, is a fundamental aspect of quantum science – Erwin Schrödinger, who came up with the name “entanglement” called it “the characteristic trait of quantum mechanics.” Entanglement is fascinating in its own right, but what makes it really special are dramatic practical applications that have become apparent in the last few years.

Real-Life Epilogue To “Erin Brockovich”: Medical Journal Retracts Fraudulent Chromium/Cancer Study (press release)

WASHINGTON, D.C. — In a real-life epilogue to “Erin Brockovich,” a peer-reviewed medical journal will retract a fraudulent article written and placed by a science-for-hire consulting firm whose CEO sits on a key federal toxics panel. The retraction follows a six-month internal review by the journal, prompted by an Environmental Working Group (EWG) investigation.The July issue of the Journal of Occupational and Environmental Medicine (JOEM), the official publication of the American College of Occupational and Environmental Medicine, will carry a retraction of a 1997 article published under the byline of two Chinese scientists, JianDong Zhang and ShuKun Li.

The article appeared to be a reversal of an earlier study by Zhang that found a significant association between chromium pollution of drinking water and higher rates of stomach cancer in villages in rural northeast China. Since its publication, the fraudulent article has influenced a number of state and federal regulatory decisions on chromium.

Article continues at:

Counseling proven better than sleeping pills for chronic insomnia; drugs actually worsened condition

(NewsTarget) According to a new report in the Journal of American Medical Association, therapy is more effective than some sleeping pills for treatment of chronic insomnia in older adults.Researchers from the University of Bergen in Norway assessed the quality and quantity of sleep for 46 people over the age of 55 who suffered from insomnia. Patients were randomly assigned to one of three groups: cognitive behavioral therapy (CBT), zopiclone (a sleeping drug), or placebo. Participants received treatment for six weeks, and afterwards researchers tracked their progress for the next six months.

Full article at: